Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $90.93

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been given an average recommendation of “Moderate Buy” by the fifteen brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $90.93.

A number of brokerages have recently commented on RARE. Piper Sandler cut their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a research report on Monday, March 17th. Morgan Stanley upped their price target on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the company an “overweight” rating in a report on Friday, May 9th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. raised their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 1,785 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total value of $72,114.00. Following the completion of the transaction, the chief financial officer now owns 106,169 shares in the company, valued at approximately $4,289,227.60. The trade was a 1.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Karah Herdman Parschauer sold 2,990 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $42.88, for a total value of $128,211.20. Following the sale, the executive vice president now owns 54,991 shares in the company, valued at $2,358,014.08. The trade was a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 125,405 shares of company stock worth $5,285,169 over the last ninety days. Corporate insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its position in Ultragenyx Pharmaceutical by 76.2% in the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 323 shares during the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 493 shares during the period. Aster Capital Management DIFC Ltd bought a new position in Ultragenyx Pharmaceutical in the fourth quarter valued at about $35,000. Human Investing LLC acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth about $42,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth about $57,000. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Stock Up 2.2%

Shares of NASDAQ:RARE opened at $35.61 on Wednesday. The company has a market cap of $3.37 billion, a price-to-earnings ratio of -5.62 and a beta of 0.34. The business has a 50 day moving average price of $36.39 and a 200 day moving average price of $41.77. Ultragenyx Pharmaceutical has a twelve month low of $29.59 and a twelve month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The business had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. During the same period in the prior year, the company posted ($2.03) earnings per share. The firm’s revenue was up 28.0% compared to the same quarter last year. Analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.